Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

REGENERON PHARMACEUTICALS

(REGN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/19/2021 02/22/2021 02/23/2021 02/24/2021 02/25/2021 Date
470.37(c) 460.58(c) 468.03(c) 458.6(c) 453.19 Last
1 129 917 1 345 550 1 705 566 1 103 374 1 125 287 Volume
-1.40% -2.08% +1.62% -2.01% -1.18% Change
More quotes
Financials (USD)
Sales 2021 11 907 M - -
Net income 2021 4 788 M - -
Net cash position 2021 9 807 M - -
P/E ratio 2021 10,7x
Yield 2021 -
Sales 2022 11 297 M - -
Net income 2022 4 174 M - -
Net cash position 2022 13 742 M - -
P/E ratio 2022 12,2x
Yield 2022 -
Capitalization 47 761 M 47 761 M -
EV / Sales 2021 3,19x
EV / Sales 2022 3,01x
Nbr of Employees 9 123
Free-Float 82,7%
More Financials
Company
Regeneron Pharmaceuticals specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Sales break down by activity as follows: - sales of products (65.5%); - supply of collaborative services (27.9%): working with Sanofi (50% of sales) and Bayer (50%); - sales of technology licenses (6.6%). The group also provides subcontracting research... 
More about the company
Notations Surperformance© of Regeneron Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
All news about REGENERON PHARMACEUTICALS
09:09aREGENERON PHARMACEUTICALS : IDMC Says REGEN-COV Shows Efficacy; Regeneron Change..
MT
07:47aROCHE : Says Committee Finds Regeneron COVID-19 Drug Has 'Clear Clinical Efficac..
MT
07:16aREGENERON PHARMACEUTICALS : to stop giving placebo in COVID-19 drug trial after ..
RE
07:02aREGENERON PHARMACEUTICALS : Independent Data Monitoring Committee Finds Clear Ef..
PR
02/23REGENERON PHARMACEUTICALS : Credit Suisse Raises Regeneron Pharmaceuticals' Pric..
MT
02/23REGENERON PHARMACEUTICALS : FDA Approves Libtayo Monotherapy for Patients with F..
AQ
02/22REGENERON PHARMACEUTICALS : Sanofi Get FDA Approval For Advanced Nonsmall Cell L..
MT
02/22REGENERON PHARMACEUTICALS : Sanofi Gets FDA OK of Libtayo in Advanced Non-Small ..
DJ
02/20REGENERON PHARMACEUTICALS : Coronavirus-hit Czechs order Regeneron antibody drug..
RE
02/16REGENERON PHARMACEUTICALS : Cantor Fitzgerald Adjusts Regeneron Pharmaceuticals'..
MT
02/15REGENERON PHARMACEUTICALS THE : Lancet Publishes Libtayo Data Showing Extended O..
AQ
02/15REGENERON PHARMACEUTICALS : Announces Investor Conference Presentations
AQ
02/12REGENERON PHARMACEUTICALS : Announces Investor Conference Presentations
PR
02/12REGENERON PHARMACEUTICALS : Sanofi Say Lung Cancer Drug Libtayo Superior to Chem..
MT
02/12REGENERON PHARMACEUTICALS : The Lancet Publishes Libtayo® (cemiplimab) Data Show..
PR
More news
News in other languages on REGENERON PHARMACEUTICALS
02/22REGENERON PHARMACEUTICALS : Sanofi erhalten erweiterte US-Zulassung für Libtayo
02/12SANOFI : données positives sur le Libtayo pour le traitement du cancer du poumon
02/05Les valeurs à suivre vendredi 5 février 2021 à Wall Street -
02/05REGENERON : le bénéfice bat le consensus
02/05REGENERON PHARMACEUTICALS : fait mieux que prévu au T4, dopé par la reprise de s..
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS
More recommendations
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 639,60 $
Last Close Price 458,60 $
Spread / Highest target 73,4%
Spread / Average Target 39,5%
Spread / Lowest Target 9,03%
EPS Revisions
Managers and Directors
NameTitle
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl Executive VP-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS-3.12%47 761
GILEAD SCIENCES, INC.9.30%79 862
VERTEX PHARMACEUTICALS-8.17%56 422
WUXI APPTEC CO., LTD.9.26%55 903
BEIGENE, LTD.29.61%30 633
BIONTECH SE40.05%27 490